Regulus Therapeutics Inc Results from the First Cohort of Patients with ADPKD in its Ongoing Phase 1b Clinical Trial of RGLS4326 Call Transcript

May 03, 2021 / 12:30PM GMT
Operator

Good morning, ladies and gentlemen, and welcome to Regulus Therapeutics Conference Call. My name is Olivia, and I will be your coordinator for today. As a reminder, this conference may be recorded. I would now like to turn the call over to the company. Please proceed.

Crispina Calsada - Regulus Therapeutics Inc. - CFO

Thank you. Good morning, everyone. My name is Crispina Calsada, and I'm the Chief Financial Officer of regular Therapeutics.

Thank you for joining us to discuss the data we announced this morning in a press release regarding the first cohort of our Phase Ib Mechanism Of Action or MOA, study of RGLS4326 in patients with autosomal dominant polycystic kidney disease or ADPKD.

We are joined this morning by Jay Hagan, Chief Executive Officer; Dr. Denis Drygen, Chief Scientific Officer; Dr. Karl Cremer, Head of Clinical Development; and Dr. Ed Lee, Head of the miR-17 program.

During our prepared remarks this morning, Jay will provide a brief summary of the program and today's results, after which we will open the line for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot